九州大学-研究者情報 [岸本淳司 (准教授) 九州大学病院 ARO次世代医療センター]

1.	Hara, T Furuno, K Yamamura, K Kishimoto, J Mizuno, Y Murata, K Onoyama, S Hatae, K Takemoto, M Ishizaki, Y Kanno, S Sato, K Motomura, Y Sakai, Y Ohga, S Yashiro, M Nakamura, Y Hara, T, Assessment of Pediatric Admissions for Kawasaki Disease or Infectious Disease During the COVID-19 State of Emergency in Japan, JAMA NETWORK OPEN, 10.1001/jamanetworkopen.2021.4475, 4, 4, 2021.04.
2.	Ryuzo Kawamori, Hiroyuki Daida, Yasushi Tanaka, Katsumi Miyauchi, Akira Kitagawa, Dobun Hayashi, Junji Kishimoto, Shunya Ikeda, Yutaka Imai, Tsutomu Yamazaki, Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J), BMC Cardiovascular Disorders, 10.1186/1471-2261-6-39, 6, 2006.10, [URL], Background: The coexistence of type 2 diabetes mellitus and hypertension increases the risk of cardiovascular diseases. The U.K. Prospective Diabetes Study has shown that blood pressure control as well as blood glucose control is efficient for prevention of complications in hypertensive patients with diabetes mellitus. However, some reports have shown that it is difficult to control the blood pressure and the concomitant use of a plurality of drugs is needed in hypertensive patients with diabetes mellitus. In recent years renin-angiotensin system depressants are increasingly used for the blood pressure control in diabetic patients. Particularly in Japan, angiotensin II (A II) antagonists are increasingly used. However, there is no definite evidence of the point of which is efficient for the control, the increase in dose of A II antagonist or the concomitant use of another drug, in hypertensive patients whose blood pressure levels are inadequately controlled with A II antagonist. Methods/Design: Hypertensive patients of age 20 years or over with type 2 diabetes mellitus who have been treated by the single use of AII antagonist at usual doses for at least 8 weeks or patients who have been treated by the concomitant use of AII antagonist and an antihypertensive drug other than calcium channel blockers and ACE inhibitors at usual doses for at least 8 weeks are included. Discussion: We designed a multi-center, prospective, randomized, open label, blinded-endpoint trial, ADVANCED-J, to compare the increases in dose of A II antagonist and the concomitant use of a Ca-channel blocker (amlodipine) and A II antagonist in hypertensive patients with diabetes mellitus, whose blood pressure levels were inadequately controlled with A II antagonist. This study is different from the usual previous studies in that home blood pressures are assessed as indicators of evaluation of blood pressure. The ADVANCED-J study may have much influence on selection of antihypertensive drugs for treatment in hypertensive patients with diabetes mellitus. It is expected to give an important hint for considering the validity of selection of anti hypertensive drugs from the aspects not only of the antihypertensive effect but medical cost-effectiveness..
3.	Tsuguharu Takahashi, Toru Ogasawara, Junji Kishimoto, Guangyao Liu, Hirotaka Asato, Takashi Nakatsuka, Eijyu Uchinuma, Kozo Nakamura, Hiroshi Kawaguchi, Tsuyoshi Takato, Kazuto Hoshi, Synergistic effects of FGF-2 with insulin or IGF-I on the proliferation of human auricular chondrocytes, Cell Transplantation, 10.3727/000000005783982675, 14, 9, 683-693, 2005.12, [URL], Chondrocyte preparation with the safety and efficiency is the first step in cartilage regenerative medicine. To prepare a chondrocyte proliferation medium that does not contain fetal bovine serum (FBS) and that provides more than a 1000-fold increase in cell numbers within approximately 1 month, we attempted to use the medium containing 5% human serum (HS), but it exerted no more than twofold increase in 2 weeks. To compensate for the limited proliferation ability in HS, we investigated the combinational effects of 12 factors [i.e., fibroblast growth factor(FGF)-2, insulin-like growth factor(IGF)-I, insulin, bone morphogenetic protein-2, parathyroid hormone, growth hormone, dexamethasone, 1α25-dihydroxy vitamin D₃, L-3,3′, 5′-triodothyronine, interleukine-1 receptor antagonist, 17β-estradiol, and testosterone] on the proliferation of human auricular chondrocytes by analysis of variance in fractional factorial design. As a result, FGF-2, dexamethasone, insulin, and IGF-I possessed promotional effects on proliferation, while the combination of FGF-2 with insulin or IGF-I synergistically enhanced the proliferation. Actually, the chondrocytes increased 7.5-fold in number in 2 weeks in a medium containing 5% HS with 10 ng/ml FGF-2, while the cell number synergistically gained a 10-12-fold increase with 5 μg/ml insulin or 100 ng/ml IGF-I in the same period. The proliferation effects were more enhanced at a concentration of 100 ng/ml for FGF-2, and especially for the combination of 100 ng/ml FGF-2 and 5 μg/ml insulin (approximately 16-fold within 2 weeks). In the long-term culture with repeated passaging, this combination provided more than 10,000-fold within 8 weeks (i.e., passage 4). Thus, we concluded that such a combination of FGF-2 with insulin or IGF-I may be useful for promotion of auricular chondrocyte proliferation in a clinical application for cartilage regeneration..
4.	Keisuke Maruyama, Nobutaka Kawahara, Masahiro Shin, Masao Tago, Junji Kishimoto, Hiroki Kurita, Shunsuke Kawamoto, Akio Morita, Takaaki Kirino, The risk of hemorrhage after radiosurgery for cerebral arteriovenous malformations, New England Journal of Medicine, 10.1056/NEJMoa040907, 352, 2, 146-153, 2005.01, [URL], BACKGROUND: Angiography shows that stereotactic radiosurgery obliterates most cerebral arteriovenous malformations after a latency period of a few years. However, the effect of this procedure on the risk of hemorrhage is poorly understood. METHODS: We performed a retrospective observational study of 500 patients with malformations who were treated with radiosurgery with use of a gamma knife. The rates of hemorrhage were assessed during three periods: before radiosurgery, between radiosurgery and the angiographic documentation of obliteration of the malformation (latency period), and after angiographic obliteration. RESULTS: Forty-two hemorrhages were documented before radiosurgery (median follow-up, 0.4 year), 23 during the latency period (median follow-up, 2.0 years), and 6 after obliteration (median follow-up, 5.4 years). As compared with the period between diagnosis and radiosurgery, the risk of hemorrhage decreased by 54 percent during the latency period (hazard ratio, 0.46; 95 percent confidence interval, 0.26 to 0.80; P=0.006) and by 88 percent after obliteration (hazard ratio, 0.12; 95 percent confidence interval, 0.05 to 0.29; P
5.	Nozomu Asukai, Hiroshi Kato, Noriyuki Kawamura, Yoshiharu Kim, Kohei Yamamoto, Junji Kishimoto, Yuko Miyake, Aya Nishizono-Maher, Reliability and validity of the Japanese-language version of the Impact of Event Scale-Revised (IES-R-J) Four studies of different traumatic events, Journal of Nervous and Mental Disease, 10.1097/00005053-200203000-00006, 190, 3, 175-182, 2002.04, [URL], The authors developed the Japanese-language version of the Impact of Event Scale-Revised (IES-R-J) and investigated its reliability and validity in four different groups: workers with lifetime mixed traumatic events, survivors of an arsenic poisoning case, survivors of the Hanshin-Awaji earthquake, and survivors of the Tokyo Metro sarin attack. Evidence includes retest reliability and internal consistency of the IES-R-J. Posttraumatic stress disorder (PTSD) and partial PTSD cases indicated significantly higher scores than non-PTSD cases. The IES-R-J can be a useful self-rating diagnostic instrument particularly for survivors with PTSD symptoms as a clinical concern (PTSD + partial PTSD) by using a 24/25 cutoff in total score. In analysis of scale structure, the majority of intrusion and hyperarousal items were subsumed under the same cluster, whereas avoidance items made up a separate cluster. Female patients indicated higher scores than male patients. A negative weak correlation between age and the score was found only among female earthquake survivors. The IES-R-J can be used as a validated instrument in future international comparative research..

主要総説, 論評, 解説, 書評, 報告書等

全てを見る→

主要学会発表等

全てを見る→

学会活動

所属学会名

日本計量生物学会

日本応用統計学会

学協会役員等への就任

2015.04～2017.03, 日本計量生物学会, 理事.

2001.04～2003.03, 日本応用統計学会, 学会誌編集委員.

2003.04～2004.03, 日本計算機統計学会, 評議員.

学会大会・会議・シンポジウム等における役割

2015.12.20～2022.12.22, East Asia Regional Biometric Conference 2015, Secretary.

学会誌・雑誌・著書の編集への参加状況

1996.01～1999.01, 日本応用統計学会, 国内, 編集委員.

学術論文等の審査

年度	外国語雑誌査読論文数	日本語雑誌査読論文数	合計
2021年度	1		1
2005年度		1
2004年度		1

研究資金

科学研究費補助金の採択状況(文部科学省、日本学術振興会)

2021年度～2025年度, 基盤研究(B), 連携, 実践的看護臨床薬理学教育モデル(iDrug)に基づいた新たな教育システムの開発.

2022年度～2027年度, 挑戦的研究（萌芽）, 分担, 新しいがん予防行動支援モデル構築への挑戦：がんサバイバー家族へのアプローチ法探索
.

2019年度～2023年度, 挑戦的研究（萌芽）, 分担, 日本人大腸がんスクリーニング検査受診率向上にむけた影響要因の探索.

2004年度～2005年度, 基盤研究(C), 分担, ドメスティック・バイオレンス被害が子どもの精神健康に及ぼす影響.

科学研究費補助金の採択状況(文部科学省、日本学術振興会以外)

2021年度～2023年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, 食道アカラシアの前駆状態とされる食道胃接合部通過障害に対するアコチアミドの有効性と安全性を検討する第II相医師主導治験.

2020年度～2020年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, シーズ開発実績に裏付けられたARO機能のリソース次元縮約と可視化に関する研究.

2020年度～2022年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, リパスジルを用いた未熟児網膜症に対する新規点眼薬の開発
.

2020年度～2022年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, レジストリを活用した慢性血栓塞栓性肺高血圧症に対するエドキサバンの適応拡大のための第Ⅲ相医師主導治験.

2019年度～2021年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, 特発性肺線維症合併進行非小細胞肺癌に対する標準治療開発に関する研究.

2018年度～2020年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, ナチュラルキラーT細胞活性化による慢性炎症制御に基づく新たな心筋症治療の実用化.

2018年度～2019年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, ポジショニング分析および経験則分析によるARO機能類型化・評価指標創出のための調査研究.

2017年度～2018年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, Brilliant Blue G250による水晶体前嚢可視化検討　第３相多施設共同医師主導治験.

2016年度～2018年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, 患者レジストリを活用した難治性クッシング症候群及びサブクリニカルクッシング症候群の病態解明と11β-HSD1阻害剤の臨床開発.

2015年度～2016年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, 高性能国産新規RNAウイルスベクターによる虚血肢治療製剤の開発.

2007年度～2007年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, 難治性心不全に対するPDE5阻害剤の効果を検証する無作為化比較試験の計画に対する研究.

2006年度～2007年度, 厚生労働科学研究費補助金 (厚生労働省), 分担, 循環器疾患領域における大規模臨床試験の手法に係る研究.

寄附金の受入状況

2009年度, 協和発酵キリン株式会社, 奨学寄付金.

2004年度, 心臓財団, アンジオテンシンⅡ受容体拮抗薬(AⅡ拮抗薬)で降圧不十分な糖尿病を伴う高血圧症患者に対するカルシウム拮抗薬追加併用群とAⅡ拮抗薬増量群の無作為化割付比較試験(ADVANCED-J).

2004年度, 大塚製薬, Study of Diabetic Atherosclerosis Prevention by Cilostazol(DAPC Study).

2005年度, 中外製薬, 虚血性心疾患のQOLに関する特別調査.

2004年度, 小野薬品, 腰部脊柱管狭窄症患者のQOLに関する研究.

九大関連コンテンツ

pure2017年10月2日から、「九州大学研究者情報」を補完するデータベースとして、Elsevier社の「Pure」による研究業績の公開を開始しました。

QIR　九州大学学術情報リポジトリシステム情報科学研究院

九州大学病院


	※ 研究者情報全体を検索する場合は右端の「すべて」を選択して下さい。